Other dual agonists of PPAR (i.e., alpha and delta—elafibranor) and pan PPAR agonists (i.e., alpha, gamma, and delta—lanifibranor) show promise in the treatment of MASH rather than steatosis [128,129]. The gene discussed is PPARA; the disease is metabolic dysfunction-associated steatohepatitis.